Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sun, Accord, Amneal And Apotex Donate Hydroxychloroquine

MedPharm Donates Hand Sanitizer While Beximco Donates PPE

Executive Summary

Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.

You may also be interested in...



Beximco Grows At Home And Abroad

Bangladeshi generics manufacturer Beximco has reported 12.3% annual sales growth for its 2020 financial year and 9.9% turnover growth for its financial first quarter ending 30 September 2020. The company remains focused on expanding its portfolio and consolidating its international presence.

Amneal ‘Hyper Focused’ On New Launches

Aiming to “aggressively expand sales,” Amneal has announced that it will be launching 15 new generics by August 2021. Amneal’s generics business has also reported growth beyond its set targets for the first quarter of 2020.

Sandoz, Mylan And Teva Take Bigger Steps To Tackle COVID-19

Sandoz is sponsoring a major hydroxychloroquine trial while other major industry players like Teva, Mylan, Apotex, Stada and Lupin are also accelerating efforts to fight the coronavirus crisis. Accord and Wavelength Pharma have stepped up their manufacturing to meet demand, as the AAM has cancelled its annual meeting.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB149787

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel